Skip to main content

Table 2 Quality assessments in order of the quality significance

From: Antidepressants and inflammatory bowel disease: a systematic review

  Kast et al. 2001 Walker et al. 1996 Scott et al. 1999 Eirund 1998 Kast 1998 Kane et al. 2003 Torras et al. 2003 Ginsburg et al. 2005 Kast 2003 Kast et al. 2004 Kast et al. 2005 Kast 2005
Length of treatment 2 years 8 weeks 6 weeks 10 months 2 years No data No NA NA NA NA NA
Follow-up Yes, regular follow-up for 2 years Yes, 2 follow-up, all patients completed Yes, detailed every day monitoring for 6 weeks. 1 follow-up after 10 months Yes, regular follow-up for 2 years 1 follow-up after 6 weeks Yes NA NA NA NA NA
Clear description of treatment Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Description of participants Yes Yes Yes Yes Yes No No NA NA NA NA NA
Validated instruments Yes Yes, but only for depression and quality of life Yes (depression), No (CD) No data No Yes No NA NA NA NA NA
Limitations - Disease type not specified, disease activity index not used. Lack of CD activity index. Focus only on depression and pain, no information about frequency of stools. No objective activity index used. No objective activity index used. Lack of explanation of patients characteristics, Lack of further follow-up, no length of treatment provided. Lack of evidence that IBD did not exist before the onset of depression, no details about length of treatment, no description of treatment and participants, no information about instruments. Guideline paper without research. IBD treated as IBS, which may not be appropriate as they are different conditions. A review study without the research. Theoretical considerations only. A letter referring to Kane et al. 2003 A review study without the research. Theoretical considerations only. A discussion referring to Kast et al. 2001 and Kane et al. 2003
Impact of treatment with antidepressants on the IBD activity Positive effect of bupropion on IBD activity (CD). Positive effect of paroxetine on IBD activity (not specified). No effect of amitriptyline on IBD activity (CD). Positive effect of paroxetine on IBD activity (UC). Positive effect of phenelzine on IBD activity (CD). Positive effect of bupropion on IBD activity (CD). Controversial paroxetine. All antidepressants recommended in irritable bowel syndrome recommended in IBD. Bupropion recommended and mirtazapine not recommended. Bupropion recommended. Bupropion recommended. Bupropion recommended.
  1. Legend:
  2. CD – Crohn's disease
  3. IBD – inflammatory bowel disease
  4. IBS – irritable bowel syndrome
  5. NA – not applicable
  6. UC – ulcerative colitis